Dthera Sciences (DTHR) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 10, 2017
Document And Entity Information
Entity Registrant Name	Dthera Sciences
Entity Central Index Key	1,586,372
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	Yes
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,492,525
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS
Cash	$ 179,100	$ 12,191
Deposits	1,000	1,000
TOTAL CURRENT ASSETS	180,100	13,191
LONG TERM ASSETS
Property and equipment, net	50,347	914
TOTAL LONG TERM ASSETS	50,347	914
TOTAL ASSETS	230,447	14,105
CURRENT LIABILITIES
Accounts payable and accrued liabilities	168,032	268,564
Accounts payable and accrued expenses, related party	0	3,515
Derivative liabilities	0	234,502
Notes payable	0	20,000
Convertible notes payable, net	0	67,345
TOTAL CURRENT LIABILITIES	168,032	593,926
TOTAL LIABILITIES	168,032	593,926
Preferred stock, 1,000,000 shares authorized. $0.001 par value; redeemable preferred stock series A, 150,000 designated; $0.0001 par value; 112,690 shares issued and outstanding as at June 30, 2017 and December 31, 2016	11	11
STOCKHOLDERS' EQUITY (DEFICIT)
Common stock 66,666,667 shares authorized; $0.001 par value; 14,431,059 and 12,060,367 shares issued and outstanding as of June 30, 2017 and December 31, 2016	14,431	12,060
Additional paid in capital	3,834,694	1,386,508
Accumulated deficit	(3,786,721)	(1,978,400)
Total Stockholders' Equity (Deficit)	62,404	(579,832)
Total Liabilities and Stockholders' Equity (Deficit)	$ 230,447	$ 14,105

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Preferred stock, par value	$ 0.001	$ .0001
Preferred stock, authorized/designated	1,000,000	1,000,000
Common stock Par value	$ 0.001	$ 0.001
Common stock, Authorized	66,666,667	66,666,667
Common stock, Issued	14,431,059	12,060,367
Common stock, outstanding	14,431,059	12,060,367
Redeemable Series A Preferred Stock [Member]
Preferred stock, authorized/designated	150,000	150,000
Preferred stock, shares issued	112,690	112,690
Preferred stock, shares outstanding	112,690	112,690

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
REVENUES
Sales	$ 0	$ 0	$ 0	$ 0
Cost of services	0	0	0	0
GROSS PROFIT	0	0	0	0
OPERATING EXPENSES
Amortization and depreciation	255	236	433	473
General and administrative	1,138,442	97,686	1,441,389	252,193
Professional fees	182,547	23,894	231,894	29,152
TOTAL OPERATING EXPENSES	1,321,244	121,816	1,673,716	281,818
OPERATING LOSS	(1,321,244)	(121,816)	(1,673,716)	(281,818)
OTHER EXPENSES
Interest expense	0	(20,132)	(185,847)	(35,838)
Impairment of intangible assets	0	(58,960)	0	(58,960)
Gain on derivative liability	0	0	142,835	0
Gain on extinguishment of debt	0	0	(91,593)	0
TOTAL OTHER EXPENSES	0	(79,092)	(134,605)	(94,798)
NET LOSS	$ (1,321,244)	$ (200,908)	$ (1,808,321)	$ (376,616)
WEIGHTED AVERAGE SHARES OUTSTANDING - Basic and diluted	7,206,135	12,060,367	13,447,438	12,060,367
Loss per share - Basic and diluted	$ (.18)	$ (.01)	$ (.13)	$ (.03)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (1,321,244)	$ (200,908)	$ (1,808,321)	$ (376,616)
Adjustments for non-cash items:
Amortization and depreciation			433	473
Amortization of debt discount			172,655	4,425
Impairment of intangible assets	0	58,960	0	58,960
Loss on extinguishment of debt	0	0	91,593	0
Gain on derivative liability	0	0	(142,835)	0
Options issued for services			1,051,538	11,785
Operating expense paid in behalf of the company			0	22,130
Changes in operating assets and liabilities:
Prepaid expenses			0	21,390
Accounts payable and accrued liabilities			(104,038)	118,795
NET CASH USED IN OPERATING ACTIVITIES			(738,975)	(138,658)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment			(49,866)	0
NET CASH USED IN INVESTING ACTIVITIES			(49,866)	0
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock			1,215,750	0
Proceeds from issuance of notes payable, related parties			50,000	85,000
Payments on notes payable			(70,000)	(61,000)
Proceeds from issuance of convertible notes payable			0	100,000
Payments on convertible notes payable			(240,000)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES			955,750	124,000
NET CHANGE IN CASH AND CASH EQUIVALENTS			166,909	(14,658)
CASH AND CASH EQUIVALENTS - Beginning of period			12,191	27,328	$ 27,328
CASH AND CASH EQUIVALENTS - End of period	$ 179,100	$ 12,580	179,100	12,580	$ 12,191
Cash paid for interest			19,890	0
NON-CASH INVESTING AND FINANCING ACTIVITIES
Common stock issued in extinguishment of debt			183,260	0
Common stock issued for assets			$ 0	$ 58,960

1. Condensed Financial Statemen

1. Condensed Financial Statements	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Financial Statements	The accompanying financial statements of Dthera Sciences (the “Company”) have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2017, and for all periods presented herein, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2016 audited financial statements. The results of operations for the periods ended June 30, 2017 and 2016 are not necessarily indicative of the operating results for the full years.

2. Going Concern

2. Going Concern	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	The Company's financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. As of the date of this Report, the Company had an accumulated deficit of $3,786,721 and no revenues to cover its operating costs, which raises substantial doubt about its ability to continue as a going concern. As of the date of this Report, the Company had not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The future of the Company as an operating business will depend on its ability to (1) obtain sufficient capital contributions and/or financing as may be required to sustain its operations and (2) to achieve adequate revenues from its operations. Management's plan to address these issues includes, (a) continued exercise of tight cost controls to conserve cash, (b) obtaining additional financing, (c) placing revenue producing services into place (d) identifying and executing on additional revenue generating opportunities. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

3. Summary of Significant Accou

3. Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Nature of Business Dthera Sciences (formerly Knowledge Machine International, Inc.) is a Nevada corporation, and was incorporated on December 27, 2012. Dthera Sciences is a digital therapeutics company based in San Diego, California, which is focused on improving the quality of life of patients and their families. The Company's lead product, ReminX, is an artificial-intelligence-powered digital therapeutic designed to improve the quality of life (QoL) and reduce anxiety in patients with Alzheimer's disease and other forms of dementia. On September 21, 2016, the Company acquired a new operating subsidiary, EveryStory, Inc., a Delaware corporation (“EveryStory”). Following the acquisition (referred to herein as the “EveryStory Transaction”), the Company’s business is to develop a Digital Therapeutic technology designed to deliver Reminiscence Therapy to certain patient populations, principally patients suffering from Alzheimer’s disease and dementia with the goal of a Quality of Life benefit and reduction in anxiety in those populations. As of the date of this Report, Dthera Sciences Operations, Inc., was our only subsidiary. In connection with the EveryStory transaction, the Company dissolved its other former subsidiary entity and terminated its prior business operations. Effective July 25, 2017, a reverse stock split of the Company’s authorized, issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-3 (one share of new common stock for each three shares of old common stock) (the “Reverse Split”), took effect in the Market, following a filing of a Certificate of Change with the State of Nevada and authorization from the Financial Industry Regulatory Authority (“FINRA”). Accounting Basis The Company’s financial statements are prepared using the accrual basis of accounting in accordance with U.S. GAAP. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates are made in relation to the allowance for doubtful accounts and the fair value of certain financial instruments. Principles of Consolidation The consolidated financial statements include the accounts of Dthera Sciences and its subsidiaries. All significant inter-Company accounts and transactions have been eliminated. Fair Value of Financial Instruments The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available. The carrying amounts of the Company's financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable & accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments. The Company accounts for its derivative liabilities, at fair value, on a recurring basis under level 3. Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under Accounting Standards Codification (“ASC”) 815, "Derivatives and Hedging" to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 "Debt with Conversion and Other Options" for consideration of any beneficial conversion feature. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of it financial instruments, including stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Multinomial Lattice model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Debt Issue Costs and Debt Discount The Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash or equity (such as warrants). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed. Stock-Based Compensation The Company accounts for share based payments in accordance with ASC 718, Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on the grant date fair value of the award. In accordance with ASC 718-10-30-9, Measurement Objective – Fair Value at Grant Date, the Company estimates the fair value of the award using a valuation technique. For this purpose, the Company uses the Black-Scholes option pricing model. The Company believes this model provides the best estimate of fair value due to its ability to incorporate inputs that change over time, such as volatility and interest rates, and to allow for actual exercise behavior of option holders. Compensation cost is recognized over the requisite service period which is generally equal to the vesting period. Upon exercise, shares issued will be newly issued shares from authorized common stock. ASC 505, "Compensation-Stock Compensation," establishes standards for the accounting for transactions in which an entity exchanges its equity instruments to non-employees for goods or services. Under this transition method, stock compensation expense includes compensation expense for all stock-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 505. Loss Per Share Basic loss per Common Share is computed by dividing losses attributable to Common shareholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per Common Share is computed by dividing loss attributable to Common shareholders by the weighted-average number of Shares of Common Stock outstanding during the period increased to include the number of additional Shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding convertible Preferred Stock, stock options, warrants, and convertible debt. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company’s Common Stock can result in a greater dilutive effect from potentially dilutive securities. For the six months ended June 30, 2017 and 2016, all of the Company’s potentially dilutive securities (warrants and options) were excluded from the computation of diluted earnings per share as they were anti-dilutive. The total number of potentially dilutive Common Shares that were excluded were 1,369,033 for the six months ended June 30, 2017. Reclassification Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation. Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09 Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In April 2017, the FASB issued ASU No. 2016-10 S ervice Concession Arrangements (Topic 853): Determining the Customer of the Operation Services (a consensus of the FASB Emerging Issues Task Force) amends certain aspects of the FASB’s new revenue standard, ASU 2014-09. ASU 2016-10 identifies performance obligations and provides licensing implementation guidance. The effective date for ASU 2016-10 is the same as the effective date of ASU No. 2014-09. The standard will be effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods within those periods. The Company is currently assessing the impact that adopting this new accounting guidance will have on its financial statements and footnote disclosures. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers Narrow-Scope Improvements and Practical Expedients Management has considered all other recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

4. Property and Equipment

4. Property and Equipment	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	The Company’s property and equipment were comprised of the following as of June 30, 2017, and December 31, 2016: June 30, December 31, Computer & Equipment $ 4,676 $ 2,816 Assets Used to Fulfill Contract Obligations 48,006 – Less: Accumulated Depreciation (2,335 ) (1,902 ) Net Property and Equipment $ 50,347 $ 914 Depreciation expense for the six months ended June 30, 2017 and 2016, was $433 and $473, respectively.

5. Intangible Assets

5. Intangible Assets	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	The Company’s intangible assets were comprised of the following of June 30, 2017, and December 31, 2016: June 30, December 31, Technology asset purchase $ – $ 58,960 Less: Accumulated Amortization – – Less: Impairment – (58,960 ) Net Intangible Assets $ – $ – The Company impaired intangible assets related to the technology asset purchase and patent purchase due to no revenue production, totaling $0 and $58,960, for the six months ended June 30, 2017 and 2016, respectively.

6. Loans Payable

6. Loans Payable	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Loans Payable	Notes Payable Notes payable consisted of the following as of June 30, 2017, and December 31, 2016: Balance December 31, 2016 $ 20,000 Cash additions 50,000 Expense additions – Cash payments (70,000 ) Conversions – Balance June 30, 2017 $ – On August 3, 2016, the Company entered into a promissory note purchase agreement with an unrelated individual for $20,000. This note was due on demand. The Company repaid this promissory note on April 13, 2017. On February 3, 2017, the Company issued a short-term note to an unrelated party individual for $50,000 due on demand. The note bore an interest rate of 10% per annum interest within the 90 day period and would increase to 20% interest if not fully paid back within 90 days. On April 9, 2017, the Company repaid the full balance of $50,000. Convertible Notes Payable Notes payable due to non-related parties consisted of the following as of June 30, 2017, and December 31, 2016: Balance December 31, 2016 $ 67,345 Cash Payments (240,000 ) Conversions – Debt discount 172,655 Balance June 30, 2017 $ – Effective September 22, 2016, the Company conducted a private offering of convertible notes (the “Note Offering”) to raise additional capital that would remain in the Company following the Closing of the EveryStory Transaction. In the convertible note offering, the Company raised an aggregate of $240,000, which was to be a component of the post-Closing capitalization of the Company. In the Note Offering, investors entered into a securities purchase agreement (the “Note SPA”) and were issued a convertible redeemable promissory note (collectively, the “Convertible Notes”). Pursuant to the terms of the Note SPA, each investor represented and warranted that it was an accredited investor and that he or she was purchasing the Convertible Notes for his or her own account, and not with a view to distribution, as well as other standard representations made in private transactions. Also pursuant to the Note SPA, the Company had the right to put an additional Convertible Note (in the same principal amount as purchased by the applicable investor) beginning on January 3, 2017, subject to certain conditions. The Convertible Notes bore interest at a rate of 10%, and were to mature on September 13, 2017, if not converted or prepaid prior to that. The Convertible Notes could convert into shares of the Company's common stock at a price for each share of Common Stock equal to 65% of the lowest closing bid price of the Common Stock as reported on the OTC Market platform on which the Company’s shares are quoted or any exchange upon which the Common Stock may be traded in the future ("Exchange"), on the date of the closing of the EveryStory Transaction. Up to 50% of the Convertible Notes could be repaid by the Company any time prior to 180 days after the issuance of the Convertible Notes, with a 30% premium to be paid in connection with the prepayment. As a result of this transaction a debt discount of $240,000 was recorded against the note. As of June 30, 2017, interest expense of $172,655 was recorded as part of the amortization of the debt discount, leaving a debt discount balance of $0. In March 2017, the Company modified the interest rate on the Convertible Notes to 15% per annum and repaid the Convertible Notes in the original principal amount of $240,000. In connection with the repayment of the Convertible Notes, the Company repaid a total of $240,000 in principal and $18,000 in interest, and agreed to issue 83,300 pre-split/27,768 shares of the Company’s common stock to the holders of the Convertible Notes. The shares of stock were issued pursuant to Section 4(a)(2) of the Securities Act of 1933 and regulations promulgated thereunder. Each of the holders of the Convertible Notes represented to the Company that it was an accredited investor, that it was acquiring the shares for its own account and for investment purposes, and not with an intent to distribute. The Company evaluated amendment under ASC 470-50, “ Debt - Modification and Extinguishment”

7. Derivative Liabilities

7. Derivative Liabilities	6 Months Ended
	Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	The Company evaluates its fair value hierarchy disclosures each quarter. The Company has convertible notes with embedded conversion features, which is accounted for as a derivative liability and measured at fair value on a recurring basis. As of June 30, 2017, this derivative liability had an estimated fair value of $0. The following table presents information about our derivative liability, which was our only financial instrument measured at fair value on a recurring basis using significant inputs other than level one inputs that are either directly or indirectly observable (Level 2) as of June 30, 2017: Balance at December 31, 2016 $ 234,502 Conversion (91,667 ) Change in Fair Value of Derivative (142,835 ) Balance at June 30, 2017 $ – The fair value of this derivative liability was calculated using the multinomial lattice models that value the derivative liability within the notes based on a probability weighted discounted cash flow model. These models are based on future projections of the various potential outcomes. The features in the notes that were analyzed and incorporated into the model included the conversion feature with the reset provisions; redemption provisions; and the default provisions. Assumptions used to calculate the fair value of the derivative liability were as follows: June 30, 2017 Expected term in years 0.51 years Risk-free interest rates 0.89% Volatility 48.05% Dividend yield 0% In addition to the assumptions above, the Company also takes into consideration whether or not the Company would participate in another round of financing and if that financing is registered or not and what that stock price would be for the financing at that time. The Company notes that the notes have matured and is no longer calculating a derivative value for these notes.

8. Preferred Stock

8. Preferred Stock	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Preferred Stock	The Company has authorized 1,000,000 shares of Preferred Stock, of which it has designated 150,000 shares of $0.0001 par value per share Series A Redeemable Preferred Stock (the “Series A Preferred”). The Series A Preferred has a stated value of $1.00 per share, of which 112,690 and 112,690 shares were issued and outstanding as of June 30, 2017, and December 31, 2016, respectively. On September 13, 2016, the Company issued the 112,690 shares of Series A Preferred to the CEO and CTO in exchange for amounts owed to them which included $6,096 of accrued expenses, $95,591 of related party loans, $10,000 of convertible notes payable and $1,003 of accrued interest on the convertible notes payable. The shares of Series A Preferred are redeemable at any time for cash on a dollar-per-dollar basis at a redemption price of $1.00 per share. If not redeemed for cash, according to the A&R Agreement the shares of Series A Preferred can be converted into shares of Common Stock using a post-split conversion price of $0.30 per share pursuant to the A&R Agreement. Series A Preferred The Series A Preferred have the following rights and preferences: · Redeemable at any time at the option of the holder for cash on a dollar-per-dollar basis at a redemption of $1.00 per share. · Convertible into shares of Common Stock using a conversion price of $0.30 per share. · No general voting rights until converted into Common Stock. · Entitled to receive dividends at a rate per annum of 8% · Liquidation preference upon a liquidation event.

9. Common Stock

9. Common Stock	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Common Stock	The Company has authorized 200,000,000 pre-split/66,666,667 post-split shares of $0.001 par value per share Common Stock, of which 43,293,151 and 36,181,101 pre-split/14,431,059 and 12,060,367 post-split shares were issued outstanding as of June 30, 2017, and December 31, 2016, respectively. Six Months Ended June 30, 2017 During six months ended June 30, 2017, pursuant to a private placement offering (the “Private Offering”) the Company issued 7,028,750 pre-split/2,342,924 post-split shares of common stock for gross proceeds of approximately $1,215,750. On March 10, 2017, the Company issued 83,300 pre-split/27,768 post-split shares of the Company’s common stock to the holders of the Convertible Notes as part of the modification and settlement of the notes, fair-valued at $183,260. Year Ended December 31, 2016 On June 5, 2016, EveryStory issued 88,000 shares of its common stock, which were exchanged for 616,133 pre-split/205,378 post-split shares of Dthera common stock for the purchase agreement for an SIT Patent for a value of $58,960. On August 3, 2016, EveryStory issued On September 15, 2016, EveryStory issued 25,000 shares of its common stock, which were exchanged for 175,038 pre-split/58,346 post-split shares of Dthera common stock valued at $16,750 for services . On September 16, 2016, EveryStory issued 37,500 shares of its common stock, which were exchanged for 263,325 pre-split/87,775 post-split shares of Dthera common stock valued at $25,125 in settlement of $60,000 of accrued consulting fees . This resulted in a gain on settlement of $34,875. On September 21, 2016, as part of the A&R Agreement, EveryStory issued 625,033 shares of its common stock, which were exchanged for 4,388,997 shares of Dthera common stock, for the conversion of debt for a value of $730,174. In connection with the A&R Agreement, the parties agreed that the prior shareholders of the Company would own an aggregate of 16,000,000 pre-split/5,333,334 post-split shares of the Company’s common stock as part of the agreement totaling $56,354. The reverse stock split is discussed in more detail in Note 1 above. From November to December 2016, the Company issued 314,500 pre-split/104,833 post-split shares of common stock at $0.20 per share for cash proceeds of $62,900, pursuant to the Private Offering.

10. Stock Purchase Options

10. Stock Purchase Options	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Purchase Options	Stock Purchase Options During the six months ended June 30, 2017, the Company did not issue any stock purchase options. As the holders of the Company’s outstanding options are employees and non-employees, the values attributable to non-employee options are remeasured on a quarterly basis and amortized over the service period and until they have fully vested over a 3 year vesting period. Stock options issued to employees are valued on the date of issuance and amortized over the service period until they have fully vested over a 3 year vesting period. The Company believes that the fair value of the stock options is more reliably measurable than the fair value of the services received. The fair value of the non-employee stock options granted was revalued at each reporting date using the Black-Scholes valuation model. As of June 30, 2017, the Company remeasured the options at a value of $4,607,123 to be recognized over the vesting period, of which $1,051,538 has been recognized. During the year ended December 31, 2016, EveryStory issued non-employee options to purchase a total of 106,100 shares of EveryStory common stock, which would exchange for 742,860 pre-split/247,620 post-split shares of Dthera common stock, which were originally valued at $63,678. EveryStory issued the options in conjunction with services. The EveryStory options were converted into Dthera options on September 21, 2016, pursuant to the A&R Agreement. As the options holders are non-employees, the values attributable to these options are remeasured on a quarterly basis and amortized over the service period and until they have fully vested over a 3 year vesting period. The Company believes that the fair value of the stock options is more reliably measurable than the fair value of the services received. The fair value of the stock options granted was revalued at each reporting date using the Black-Scholes valuation model. As of December 31, 2016, the Company remeasured the options at a value of $1,609,669 to be recognized over the vesting period, of which $199,969 has been recognized. The following table summarizes the changes in options outstanding of the Company during the six months ending June 30, 2017: Number of Weighted Average Exercise Price $ Outstanding, December 31, 2016 1,382,351 0.29 Outstanding, June 30, 2017 1,382,351 0.29 Exercisable, June 30, 2017 1,134,727 0.29 As of June 30, 2017, the Company had $3,549,536 in unrecognized expense related to future vesting of stock options.

11. Fair Value Measurements

11. Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Liabilities measured at fair value on a recurring basis at June 30, 2017, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ 4,682,580 $ – $ 4,682,580 Fair value of derivatives $ – $ – $ – $ – Liabilities measured at fair value on a recurring basis at December 31, 2016, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ – $ 1,609,699 $ 1,609,699 Fair value of derivatives $ – $ 234,502 $ – $ 234,502 Fair value is calculated using the Black-Scholes options pricing model for options and the Binomial Lattice model for derivative liabilities.

12. Subsequent Events

12. Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	In accordance with ASC 855, Company’s management reviewed all material events through the date of this filing and determined that there were the following material subsequent events to report: Reverse Stock Split On July 25, 2017, a reverse stock split (the “Reverse Split”) of the Company’s authorized and outstanding common stock took effect. The ratio of the Reverse Split was 1:3, meaning one new share for each three old shares of the Company’s common stock. In lieu of issuing fractional shares, the Company’s transfer agent was instructed to round up to the nearest whole share. Following the Reverse Split, the Company had 66,666,667 shares of common stock authorized, and had 14,431,059 shares of common stock outstanding. Pursuant to Nevada corporate law, the Reverse Split was approved by the Board of Directors. Because the Reverse Split applied both to the outstanding shares and to the authorized shares of common stock of the Company, no shareholder approval was required. Private Offerings On July 12, 2017, the Company commenced two parallel private offerings of its securities. The aggregate amount sought to be raised in the two offerings is $975,000. Investor Offering The first private offering is offered to investors (the “Investor Offering”), in which the Company is selling units (the “Units”) which consist of four shares of the Company’s common stock and warrants to purchase one additional share of common stock. The per unit price is $0.04 pre-split/$0.12 post-split, and the exercise price for the warrants is $0.15 pre-split/$0.45 post-split. The warrants cannot be exercised until two years from the purchase date (subject to certain conditions), and expire four years after the purchase date. As of August 10, 2017, the Company had sold an aggregate of 11,061,466 shares of its common stock for $331,841 and issued warrants to purchase an additional 3,227,854 shares in the Investor Offering. The foregoing summary of the terms and conditions of the Investor Offering does not purport to be complete, and is qualified in its entirety by reference to the full text of the Investment Unit Purchase Agreement and the form of warrant, which were filed as exhibits to a Current Report on Form 8-K filed on July 25, 2017. Employee/Consultant Offering The second private offering is being offered to employees and consultants of the Company (the “Employee Offering”), in which the Company is selling shares of its common stock at a purchase price of $0.03 per share, the same price as in the Investor Offering; however, there are no warrants in the Employee Offering. The shares sold in the Employee Offering include restrictions on their resale, and the Company reserves the right to repurchase the shares (the “Repurchase Right”) on terms as agreed between the Company and the employee or consultant. Per the Employee and Consultant Share Purchase Agreement, the Company’s Repurchase Rights will terminate (subject to certain conditions) following a term of not less than 5 months or more than 36 months from the purchase date. As of August 10, 2017, the Company had sold an aggregate of 0 shares of its common stock for $0 in the Employee Offering. The foregoing summary of the terms and conditions of the Employee Offering does not purport to be complete, and is qualified in its entirety by reference to the full text of the Employee and Consultant Share Purchase Agreement which was filed as an exhibit to a Current Report on Form 8-K filed on July 25, 2017. Preferred Shares On August 2, 2017, the Company redeemed 42,690 shares of Series A Preferred with a stated value of $1.00 per share for $42,690.

3. Summary of Significant Acc18

3. Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Nature of Business	Nature of Business Dthera Sciences (formerly Knowledge Machine International, Inc.) is a Nevada corporation, and was incorporated on December 27, 2012. Dthera Sciences is a digital therapeutics company based in San Diego, California, which is focused on improving the quality of life of patients and their families. The Company's lead product, ReminX, is an artificial-intelligence-powered digital therapeutic designed to improve the quality of life (QoL) and reduce anxiety in patients with Alzheimer's disease and other forms of dementia. On September 21, 2016, the Company acquired a new operating subsidiary, EveryStory, Inc., a Delaware corporation (“EveryStory”). Following the acquisition (referred to herein as the “EveryStory Transaction”), the Company’s business is to develop a Digital Therapeutic technology designed to deliver Reminiscence Therapy to certain patient populations, principally patients suffering from Alzheimer’s disease and dementia with the goal of a Quality of Life benefit and reduction in anxiety in those populations. As of the date of this Report, Dthera Sciences Operations, Inc., was our only subsidiary. In connection with the EveryStory transaction, the Company dissolved its other former subsidiary entity and terminated its prior business operations. Effective July 25, 2017, a reverse stock split of the Company’s authorized, issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-3 (one share of new common stock for each three shares of old common stock) (the “Reverse Split”), took effect in the Market, following a filing of a Certificate of Change with the State of Nevada and authorization from the Financial Industry Regulatory Authority (“FINRA”).
Accounting Basis	Accounting Basis The Company’s financial statements are prepared using the accrual basis of accounting in accordance with U.S. GAAP.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates are made in relation to the allowance for doubtful accounts and the fair value of certain financial instruments.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Dthera Sciences and its subsidiaries. All significant inter-Company accounts and transactions have been eliminated.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level. The following are the hierarchical levels of inputs to measure fair value: Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities. Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available. The carrying amounts of the Company's financial assets and liabilities, such as cash, prepaid expenses, other current assets, accounts payable & accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments. The Company accounts for its derivative liabilities, at fair value, on a recurring basis under level 3.
Embedded Conversion Features	Embedded Conversion Features The Company evaluates embedded conversion features within convertible debt under Accounting Standards Codification (“ASC”) 815, "Derivatives and Hedging" to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 "Debt with Conversion and Other Options" for consideration of any beneficial conversion feature.
Derivative Financial Instruments	Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of it financial instruments, including stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Multinomial Lattice model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
Debt Issue Costs and Debt Discount	Debt Issue Costs and Debt Discount The Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash or equity (such as warrants). These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for share based payments in accordance with ASC 718, Compensation - Stock Compensation, which requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on the grant date fair value of the award. In accordance with ASC 718-10-30-9, Measurement Objective – Fair Value at Grant Date, the Company estimates the fair value of the award using a valuation technique. For this purpose, the Company uses the Black-Scholes option pricing model. The Company believes this model provides the best estimate of fair value due to its ability to incorporate inputs that change over time, such as volatility and interest rates, and to allow for actual exercise behavior of option holders. Compensation cost is recognized over the requisite service period which is generally equal to the vesting period. Upon exercise, shares issued will be newly issued shares from authorized common stock. ASC 505, "Compensation-Stock Compensation," establishes standards for the accounting for transactions in which an entity exchanges its equity instruments to non-employees for goods or services. Under this transition method, stock compensation expense includes compensation expense for all stock-based compensation awards granted on or after January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of ASC 505.
Loss Per Share	Loss Per Share Basic loss per Common Share is computed by dividing losses attributable to Common shareholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per Common Share is computed by dividing loss attributable to Common shareholders by the weighted-average number of Shares of Common Stock outstanding during the period increased to include the number of additional Shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding convertible Preferred Stock, stock options, warrants, and convertible debt. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company’s Common Stock can result in a greater dilutive effect from potentially dilutive securities. For the six months ended June 30, 2017 and 2016, all of the Company’s potentially dilutive securities (warrants and options) were excluded from the computation of diluted earnings per share as they were anti-dilutive. The total number of potentially dilutive Common Shares that were excluded were 1,369,033 for the six months ended June 30, 2017.
Reclassification	Reclassification Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09 Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In April 2017, the FASB issued ASU No. 2016-10 S ervice Concession Arrangements (Topic 853): Determining the Customer of the Operation Services (a consensus of the FASB Emerging Issues Task Force) amends certain aspects of the FASB’s new revenue standard, ASU 2014-09. ASU 2016-10 identifies performance obligations and provides licensing implementation guidance. The effective date for ASU 2016-10 is the same as the effective date of ASU No. 2014-09. The standard will be effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods within those periods. The Company is currently assessing the impact that adopting this new accounting guidance will have on its financial statements and footnote disclosures. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers Narrow-Scope Improvements and Practical Expedients Management has considered all other recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s consolidated financial statements.

4. Property and Equipment (Tabl

4. Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Property and equipment schedule	June 30, December 31, Computer & Equipment $ 4,676 $ 2,816 Assets Used to Fulfill Contract Obligations 48,006 – Less: Accumulated Depreciation (2,335 ) (1,902 ) Net Property and Equipment $ 50,347 $ 914

5. Intangible Assets (Tables)

5. Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets	June 30, December 31, Technology asset purchase $ – $ 58,960 Less: Accumulated Amortization – – Less: Impairment – (58,960 ) Net Intangible Assets $ – $ –

6. Loans Payable (Tables)

6. Loans Payable (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of notes payable	Balance December 31, 2016 $ 20,000 Cash additions 50,000 Expense additions – Cash payments (70,000 ) Conversions – Balance June 30, 2017 $ –
Schedule of convertible notes payable	Balance December 31, 2016 $ 67,345 Cash Payments (240,000 ) Conversions – Debt discount 172,655 Balance June 30, 2017 $ –

7. Derivative Liabilities (Tabl

7. Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liability - Level 2	Balance at December 31, 2016 $ 234,502 Conversion (91,667 ) Change in Fair Value of Derivative (142,835 ) Balance at June 30, 2017 $ –
Assumptions	June 30, 2017 Expected term in years 0.51 years Risk-free interest rates 0.89% Volatility 48.05% Dividend yield 0%

10. Stock Purchase Options (Tab

10. Stock Purchase Options (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Option activity	Number of Weighted Average Exercise Price $ Outstanding, December 31, 2016 1,382,351 0.29 Outstanding, June 30, 2017 1,382,351 0.29 Exercisable, June 30, 2017 1,134,727 0.29

11. Fair Value Measurements (Ta

11. Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	Liabilities measured at fair value on a recurring basis at June 30, 2017, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ 4,682,580 $ – $ 4,682,580 Fair value of derivatives $ – $ – $ – $ – Liabilities measured at fair value on a recurring basis at December 31, 2016, are summarized as follows: Level 1 Level 2 Level 3 Total Fair value of options $ – $ – $ 1,609,699 $ 1,609,699 Fair value of derivatives $ – $ 234,502 $ – $ 234,502 Fair value is calculated using the Black-Scholes options pricing model for options and the Binomial Lattice model for derivative liabilities.

2. Going Concern (Details Narra

2. Going Concern (Details Narrative) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (3,786,721)	$ (1,978,400)

3. Summary of Significant Acc26

3. Summary of Significant Accounting Policies (Details Narrative)	6 Months Ended
	Jun. 30, 2017shares
Accounting Policies [Abstract]
Antidilutive shares excluded from EPS	1,369,033

4. Property and Equipment (Deta

4. Property and Equipment (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Computer and equipment	$ 4,676	$ 2,816
Assets used to fulfill contract obligations	48,006	0
Less: Accumulated depreciation	(2,335)	(1,902)
Net property and equipment	$ 50,347	$ 914

4. Property and Equipment (De28

4. Property and Equipment (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 433	$ 473

5. Intangible Assets (Details)

5. Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Technology asset purchase	$ 0		$ 0		$ 58,960
Less: Accumulated Amortization	0		0		0
Less: Impairment	0	$ (58,960)	0	$ (58,960)
Net Intangible Assets	$ 0		$ 0		$ 0

6. Loans Payable (Details)

6. Loans Payable (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash payments	$ (70,000)	$ (61,000)
Notes Payable [Member]
Balance, beginning	20,000
Cash additions	50,000
Expense additions	0
Cash payments	(70,000)
Conversions	0
Balance, ending	0
Convertible Notes Payable [Member]
Balance, beginning	67,345
Cash payments	(240,000)
Conversions	0
Debt discount from debt issuance costs	172,655
Balance, ending	$ 0

6. Loans Payable (Details Narra

6. Loans Payable (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Repayment of convertible notes	$ 240,000	$ 0
Convertible Notes Payable [Member]
Debt discount	0		$ 240,000
Interest expense	172,655
Repayment of convertible notes	240,000
Repayment of interest	18,000
Stock issued on extinguishment of debt	27,768
Loss on extinguishment of debt	$ (91,593)
Note Payable 1 [Member]
Debt issuance date	Aug. 3, 2016
Debt face value	$ 20,000
Note Payable 2[Member]
Debt issuance date	Feb. 3, 2017
Debt face value	$ 50,000
Debt stated interest rate	10.00%

7. Derivative Liabilities (Deta

7. Derivative Liabilities (Details - Level 2) - Convertible Notes [Member]	6 Months Ended
	Jun. 30, 2017USD ($)
Derivative liability, beginning balance	$ 234,502
Conversion	(91,667)
Change in Fair Value of Derivative	(142,835)
Derivative liability, ending balance	$ 0

7. Derivative Liabilities (De33

7. Derivative Liabilities (Details - Assumptions)	6 Months Ended
	Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Expected term in years	0.51 years
Risk-free interest rates	0.89%
Volatility	48.05%
Dividend yield	0.00%

8. Preferred Stock (Details Nar

8. Preferred Stock (Details Narrative) - Redeemable Series A Preferred Stock [Member] - CEO and CTO [Member]	12 Months Ended
	Dec. 31, 2016USD ($)shares
Stock issued for settlement of debt, shares issued | shares	112,690
Accrued Expenses [Member]
Stock issued for settlement of debt, amount	$ 6,096
Related Party Loans [Member]
Stock issued for settlement of debt, amount	95,591
Convertible Notes Payable [Member]
Stock issued for settlement of debt, amount	10,000
Accrued Interest [Member]
Stock issued for settlement of debt, amount	$ 1,003

9. Common Stock (Details Narrat

9. Common Stock (Details Narrative) - USD ($)	2 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Proceeds from issuance of common stock				$ 1,215,750	$ 0
Gain on settlement of debt		$ 0	$ 0	$ (91,593)	$ 0
Dthera Sciences [Member] | Common Stock [Member] | Post-Split Shares [Member]
Stock issued for services, shares						58,346
Stock issued for services, value						$ 16,750
Stock issued for patent, shares						205,378
Stock issued for patent, value						$ 58,960
Stock issued for settlement of accrued consulting fees, shares						87,775
Stock issued for settlement of accrued consulting fees, value						$ 25,125
Gain on settlement of debt						$ 34,875
Conversion of debt, stock issued						4,388,997
Conversion of debt, amount converted						$ 730,174
Conversion of interest, stock issued						23,338
Conversion of interest, amount converted						$ 6,700
EveryStory | Post-Split Shares [Member]
Shares owned post-split	5,333,334					5,333,334
Value of shares owned	$ 56,354					$ 56,354
Convertible Notes Modification [Member]
Stock issued for modification and settlement of notes, shares issued				27,768
Stock issued for modification and settlement of notes, value				$ 183,260
Private Offering [Member]
Common stock issued for cash, shares issued	104,833			2,342,924
Proceeds from private placement	$ 62,900			$ 1,215,750

10. Stock Purchase Options (Det

10. Stock Purchase Options (Details - Option activity) - Options [Member]	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Number of Options
Options outstanding, beginning balance | shares	1,382,351
Options granted | shares	0
Options outstanding, ending balance | shares	1,382,351
Options exercisable | shares	1,134,727
Weighted Average Exercise Price
Weighted average exercise price, options outstanding, beginning balance | $ / shares	$ .29
Weighted average exercise price, options granted | $ / shares	0
Weighted average exercise price, options outstanding, ending balance | $ / shares	.29
Weighted average exercise price, options exercisable | $ / shares	$ .29

10. Stock Purchase Options (D37

10. Stock Purchase Options (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Unrecognized stock option expense	$ 3,355,616
Options [Member] | Dthera Sciences [Member] | Post-Split Shares [Member]
Options granted		247,620
Options granted, value	4,607,123	$ 1,609,669
Share based compensation	$ 1,051,538	$ 199,969

11. Fair Value Measurements (De

11. Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Fair value of options	$ 4,682,580	$ 1,609,699
Fair value of derivatives	0	234,502
Fair Value, Inputs, Level 1 [Member]
Fair value of options	0	0
Fair value of derivatives	0	0
Fair Value, Inputs, Level 2 [Member]
Fair value of options	4,682,580	0
Fair value of derivatives	0	234,502
Fair Value, Inputs, Level 3 [Member]
Fair value of options	0	1,609,699
Fair value of derivatives	$ 0	$ 0